The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

[1]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[2]  M. Kudo,et al.  Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. , 2018 .

[3]  M. Esteller,et al.  Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. , 2017, Gastroenterology.

[4]  P. Galle,et al.  Immune oncology in hepatocellular carcinoma—hype and hope , 2017, The Lancet.

[5]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[6]  M. Vignali,et al.  Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis , 2017, PLoS medicine.

[7]  S. Steinberg,et al.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. , 2017, Journal of hepatology.

[8]  T. Greten,et al.  Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma , 2017, Nature Reviews Gastroenterology &Hepatology.

[9]  T. Greten,et al.  Targets for immunotherapy of liver cancer. , 2017, Journal of hepatology.

[10]  J. Becker,et al.  T cell receptor repertoire usage in cancer as a surrogate marker for immune responses , 2017, Seminars in Immunopathology.

[11]  H. Kohrt,et al.  Biomarkers associated with checkpoint inhibitors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[13]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[14]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[15]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[16]  T. Greten,et al.  Hepatocellular Carcinoma from an Immunologic Perspective , 2013, Clinical Cancer Research.

[17]  T. Greten,et al.  Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies , 2013, Cancer Immunology, Immunotherapy.

[18]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[19]  C. Desmarais,et al.  Ultra-sensitive detection of rare T cell clones. , 2012, Journal of immunological methods.

[20]  Abigail Wacher,et al.  Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.